The biology and clinical uses of blood stem cells
LB To, DN Haylock, PJ Simmons… - Blood, The Journal of …, 1997 - ashpublications.org
''It seems more than ever likely that blood-derived stem tive capacity. 47-49 In the allogeneic
setting, mobilized blood cells have also been used instead of BM. 50 Umbilical cord cells …
setting, mobilized blood cells have also been used instead of BM. 50 Umbilical cord cells …
Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision‐making about cancer treatments
M Mazumdar, JR Glassman - Statistics in medicine, 2000 - Wiley Online Library
Categorizing prognostic variables is essential for their use in clinical decision‐making. Often
a single cutpoint that stratifies patients into high‐risk and low‐risk categories is sought …
a single cutpoint that stratifies patients into high‐risk and low‐risk categories is sought …
An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of …
CH Weaver, B Hazelton, R Birch, P Palmer, C Allen… - 1995 - ashpublications.org
The CD34 antigen is expressed by committed and uncommitted hematopoietic progenitor
cells and is increasingly used to assess stem cell content of peripheral blood progenitor cell …
cells and is increasingly used to assess stem cell content of peripheral blood progenitor cell …
Factors that influence collection and engraftment of autologous peripheral-blood stem cells.
W Bensinger, F Appelbaum, S Rowley… - Journal of Clinical …, 1995 - ascopubs.org
PURPOSE To analyze factors that affect the collection of peripheral-blood stem cells (PBSC)
before transplant and the tempo of engraftment after transplant. PATIENTS AND METHODS …
before transplant and the tempo of engraftment after transplant. PATIENTS AND METHODS …
Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma
R Haas, R Mohle, S Fruhauf, H Goldschmidt, B Witt… - 1994 - ashpublications.org
For patients with advanced-stage or poor-prognosis malignant lymphoma, high-dose
therapy with peripheral blood progenitor cell (PBPC) support may become a first-line …
therapy with peripheral blood progenitor cell (PBPC) support may become a first-line …
Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG‐CSF): an analysis of factors correlating with the tempo of …
WI Bensinger, K Longin, F Appelbaum… - British journal of …, 1994 - Wiley Online Library
Factors affecting mobilization and engraftment were analysed in 54 patients undergoing
transplant using autologous PBSCs mobilized with high‐dose recombinant granulocyte …
transplant using autologous PBSCs mobilized with high‐dose recombinant granulocyte …
Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation
U Narayanasami, R Kanteti, J Morelli… - Blood, The Journal …, 2001 - ashpublications.org
Peripheral blood cell (PBC) rescue has become the mainstay for autologous transplantation
in patients with lymphoma, multiple myeloma, and solid tumors. Different methods of …
in patients with lymphoma, multiple myeloma, and solid tumors. Different methods of …
Filgrastim: a review of its pharmacological properties and therapeutic efficacy in neutropenia
JE Frampton, CR Lee, D Faulds - Drugs, 1994 - Springer
Synopsis Filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF),
has identical biological activity to that of endogenous human G-CSF, but differs in that it …
has identical biological activity to that of endogenous human G-CSF, but differs in that it …
Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs: a randomized, controlled trial
O Hartmann, AGL Corroller, D Blaise… - Annals of internal …, 1997 - acpjournals.org
Background: Previous studies have suggested that peripheral blood stem cell (PBC)
transplantation has an advantage over autologous bone marrow transplantation. Objective …
transplantation has an advantage over autologous bone marrow transplantation. Objective …
Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery
EJ Shpall, R Champlin, JA Glaspy - Biology of Blood and Marrow …, 1998 - astctjournal.org
The CD34+ cell surface antigen is expressed on progenitor cells required for blood stem cell
transplantation. The number of cells expressing CD34+ can be used to assess the …
transplantation. The number of cells expressing CD34+ can be used to assess the …